vs
Side-by-side financial comparison of First Foundation Inc. (FFWM) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $48.4M, roughly 1.2× First Foundation Inc.). On growth, First Foundation Inc. posted the faster year-over-year revenue change (421.7% vs 94.1%). First Foundation Inc. produced more free cash flow last quarter ($-35.2M vs $-167.0M).
John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
FFWM vs PHAT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.4M | $57.6M |
| Net Profit | $-8.0M | — |
| Gross Margin | — | 86.7% |
| Operating Margin | -97.5% | — |
| Net Margin | -97.9% | — |
| Revenue YoY | 421.7% | 94.1% |
| Net Profit YoY | 43.0% | 71.6% |
| EPS (diluted) | $-0.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $48.4M | $57.6M | ||
| Q3 25 | $63.6M | $49.5M | ||
| Q2 25 | $51.4M | $39.5M | ||
| Q1 25 | $71.4M | $28.5M | ||
| Q4 24 | $9.3M | $29.7M | ||
| Q3 24 | $9.2M | $16.4M | ||
| Q2 24 | $57.5M | $7.3M | ||
| Q1 24 | $51.1M | — |
| Q4 25 | $-8.0M | — | ||
| Q3 25 | $-146.3M | $-30.0M | ||
| Q2 25 | $-7.7M | $-75.8M | ||
| Q1 25 | $6.9M | $-94.3M | ||
| Q4 24 | $-14.1M | — | ||
| Q3 24 | $-82.2M | $-85.6M | ||
| Q2 24 | $3.1M | $-91.4M | ||
| Q1 24 | $793.0K | — |
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | — | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | — | 81.2% | ||
| Q1 24 | — | — |
| Q4 25 | -97.5% | — | ||
| Q3 25 | -92.7% | -30.8% | ||
| Q2 25 | -21.1% | -151.7% | ||
| Q1 25 | 8.8% | -276.5% | ||
| Q4 24 | -247.7% | — | ||
| Q3 24 | -1276.7% | -433.0% | ||
| Q2 24 | 4.6% | -1055.4% | ||
| Q1 24 | -0.2% | — |
| Q4 25 | -97.9% | — | ||
| Q3 25 | -230.1% | -60.5% | ||
| Q2 25 | -15.0% | -191.9% | ||
| Q1 25 | 9.7% | -330.7% | ||
| Q4 24 | -152.2% | — | ||
| Q3 24 | -896.9% | -523.3% | ||
| Q2 24 | 5.4% | -1248.6% | ||
| Q1 24 | 1.6% | — |
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-1.78 | $-0.41 | ||
| Q2 25 | $-0.09 | $-1.05 | ||
| Q1 25 | $0.08 | $-1.31 | ||
| Q4 24 | $-0.24 | — | ||
| Q3 24 | $-1.23 | $-1.32 | ||
| Q2 24 | $0.05 | $-1.56 | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6B | $130.0M |
| Total DebtLower is stronger | — | $209.1M |
| Stockholders' EquityBook value | $912.6M | $-438.2M |
| Total Assets | $11.9B | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $130.0M | ||
| Q3 25 | $1.7B | $135.2M | ||
| Q2 25 | $1.1B | $149.6M | ||
| Q1 25 | $1.0B | $212.3M | ||
| Q4 24 | $1.0B | $297.3M | ||
| Q3 24 | $1.1B | $334.7M | ||
| Q2 24 | $1.4B | $276.2M | ||
| Q1 24 | $1.6B | — |
| Q4 25 | — | $209.1M | ||
| Q3 25 | — | $207.1M | ||
| Q2 25 | — | $205.1M | ||
| Q1 25 | — | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | — | $175.7M | ||
| Q2 24 | — | $174.4M | ||
| Q1 24 | — | — |
| Q4 25 | $912.6M | $-438.2M | ||
| Q3 25 | $917.9M | $-422.5M | ||
| Q2 25 | $1.1B | $-405.8M | ||
| Q1 25 | $1.1B | $-338.4M | ||
| Q4 24 | $1.1B | $-253.6M | ||
| Q3 24 | $1.1B | $-187.1M | ||
| Q2 24 | $933.2M | $-233.8M | ||
| Q1 24 | $928.7M | — |
| Q4 25 | $11.9B | $259.1M | ||
| Q3 25 | $11.9B | $240.3M | ||
| Q2 25 | $11.6B | $250.2M | ||
| Q1 25 | $12.6B | $294.2M | ||
| Q4 24 | $12.6B | $378.3M | ||
| Q3 24 | $13.4B | $387.0M | ||
| Q2 24 | $13.7B | $319.4M | ||
| Q1 24 | $13.6B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.9M | $-166.8M |
| Free Cash FlowOCF − Capex | $-35.2M | $-167.0M |
| FCF MarginFCF / Revenue | -72.8% | -290.0% |
| Capex IntensityCapex / Revenue | 6.9% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-45.9M | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.9M | $-166.8M | ||
| Q3 25 | $9.2M | $-14.1M | ||
| Q2 25 | $-16.3M | $-62.7M | ||
| Q1 25 | $-552.0K | $-84.9M | ||
| Q4 24 | $-8.7M | $-266.8M | ||
| Q3 24 | $14.2M | $-63.6M | ||
| Q2 24 | $-9.1M | $-70.7M | ||
| Q1 24 | $7.2M | — |
| Q4 25 | $-35.2M | $-167.0M | ||
| Q3 25 | $8.6M | $-14.1M | ||
| Q2 25 | $-16.7M | $-62.8M | ||
| Q1 25 | $-2.5M | $-84.9M | ||
| Q4 24 | $-11.4M | $-266.9M | ||
| Q3 24 | $13.4M | $-63.6M | ||
| Q2 24 | $-9.4M | $-70.8M | ||
| Q1 24 | $5.9M | — |
| Q4 25 | -72.8% | -290.0% | ||
| Q3 25 | 13.5% | -28.6% | ||
| Q2 25 | -32.4% | -159.0% | ||
| Q1 25 | -3.5% | -297.9% | ||
| Q4 24 | -123.5% | -899.8% | ||
| Q3 24 | 146.2% | -389.0% | ||
| Q2 24 | -16.3% | -966.2% | ||
| Q1 24 | 11.6% | — |
| Q4 25 | 6.9% | 0.4% | ||
| Q3 25 | 1.0% | 0.1% | ||
| Q2 25 | 0.8% | 0.2% | ||
| Q1 25 | 2.8% | 0.1% | ||
| Q4 24 | 29.4% | 0.5% | ||
| Q3 24 | 9.0% | 0.3% | ||
| Q2 24 | 0.4% | 0.6% | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.08× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.96× | — | ||
| Q1 24 | 9.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
